Wave Life Sciences Ltd.
Wave Life Sciences Ltd. (WVE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · WVE · as of Sep 30, 2025
Ownership Breakdown
207
Institutional Holders
▲ 25 vs Q2
$1.05B
Total Inst. Value
▲ $148.50M vs Q2
192.40M
Shares Outstanding
freeFloat 82.35%
143.68M
13F Shares Held
▲ 4.74M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
WVE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 18.20M | 11.10% | 11.10% | $133.24B | Nov 14, 2025 | — held |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 14.57M | 8.88% | 8.88% | $106.64B | Nov 14, 2025 | ▼ 448.7K |
BLACKROCK, INC. pharmaceutical preparations | 10.43M | 6.36% | 6.36% | $76.35B | Nov 12, 2025 | ▲ 47.1K |
MAVERICK CAPITAL LTD pharmaceutical preparations | 8.39M | 5.12% | 5.12% | $61.43B | Nov 14, 2025 | ▲ 130.2K |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 6.30M | 3.84% | 3.84% | $46.10B | Nov 14, 2025 | ▼ 233.5K |
M28 CAPITAL MANAGEMENT LP pharmaceutical preparations | 5.66M | 3.45% | 3.45% | $41.46B | Nov 13, 2025 | — held |
FMR LLC pharmaceutical preparations | 5.13M | 3.13% | 3.13% | $37.55B | Nov 13, 2025 | ▲ 4.51M |
KYNAM CAPITAL MANAGEMENT, LP pharmaceutical preparations | 4.56M | 2.78% | 2.78% | $33.38B | Nov 14, 2025 | — held |
683 CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 4.15M | 2.53% | 2.53% | $30.38B | Nov 14, 2025 | ▲ 50.0K |
BELLEVUE GROUP AG pharmaceutical preparations | 4.09M | 2.50% | 2.50% | $29.97B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+13.81M shares1
New Positions
first time holders15
Decreased
−6.78M shares0
Sold Out
fully exitedNet shares change (top 50)
+7.03M
+13.81M / −6.78M
Net new holders
+10
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
WVE insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
16
Buy transactions
12
Sell transactions
1.33
Buy/Sell ratio
$4M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P.
| Mar 30, 2026 | Purchase | 971,091 | $6.50 | $6.31M | 26.98M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| Mar 27, 2026 | Purchase | 2,495,623 | $6.43 | $16.05M | 26.00M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| Mar 26, 2026 | Purchase | 351,224 | $6.38 | $2.24M | 23.51M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P.
| Mar 26, 2026 | Purchase | 4,954,558 | $6.06 | $30.02M | 23.16M | Form 4 ↗ |
TAKANASHI KEN director | Mar 23, 2026 | C-Conversion | 3,901,348 | — | — | 9.61M | Form 4 ↗ |
TAKANASHI KEN director | Mar 23, 2026 | C-Conversion | 3,901,348 | — | — | 0 | Form 4 ↗ |
Francis Chris See Remarks | Feb 26, 2026 | Sale | 17,900 | $15.09 | $270.2K | 61.9K | Form 4 ↗ |
Francis Chris See Remarks | Feb 26, 2026 | Sale | 15,294 | $15.00 | $229.4K | 61.9K | Form 4 ↗ |
Moran Kyle Chief Financial Officer | Feb 5, 2026 | Award | 273,750 | $12.75 | $3.49M | 273.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Wave Life Sciences Ltd. (WVE) is primarily owned by institutional investors, who hold approximately 74.7% of total shares outstanding. Company insiders own approximately 17.65%, while retail and public investors account for the remaining 7.67%.
The largest institutional shareholder of Wave Life Sciences Ltd. is RA CAPITAL MANAGEMENT, L.P., holding approximately 18.20 million shares — equal to 11.10% of outstanding shares — as of September 30, 2025.
A total of 207 institutional investors currently hold WVE stock, with a combined institutional value of approximately $1.05 billion as of the most recent 13F filing period.
Frequently asked questions
WVE ownershipWave Life Sciences Ltd. (WVE) is primarily owned by institutional investors, who hold approximately 74.7% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 11.10% stake. Company insiders hold 17.65%. Data sourced from SEC Form 13F as of September 30, 2025.